english.prescrire.org > Spotlight > Archives : 2025 > Errors related to brand names: the EMA can still do more

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

Errors related to brand names: the EMA can still do more

 Advancing Healthcare Policy  In March 2022, Prescrire responded to a public consultation launched by the European Medicines Agency (EMA) in preparation for the 7th revision of its guideline on the acceptability of brand names for drugs authorised via the centralised procedure. The new version of this guideline was published in December 2023. For drugs that are the subject of a European marketing authorisation application, the EMA is stepping up its efforts to prevent medication errors related to brand names. But it still does not encourage systematic use of international nonproprietary names.
Full article (3 pages) available for download (FREE)

 ©Prescrire 1 March 2025

Source: "Prevention of errors related to authorised brand names: the EMA can still do more" Prescrire Int 2025; 34 (268): 80-83. FREE.

Filet

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook  
 
 
See also:

"Consultation on proprietary
drug names"
Prescrire Int 2023;
32 (246): 82.
Subscribers only
 
"A common language"
Prescrire Int 2020;
29 (220): 265.
Subscribers only